Attorneys-at-law
12 UPC Representatives · 12 SEP Litigators
Germany · And other UPC member states
Short self-description
PENTARC is a next-generation IP and patent litigation boutique, founded in October 2025. With one of the most experienced UPC litigation teams in Europe, it has been described as “the largest spin-off in the German IP market in the past 25 years.” The firm unites decades of courtroom experience.
Main practice areas: Patent litigation, IP litigation, IP strategy, license and R&D agreements, IP-related arbitration, and more.
Industry/technology focus: Mechanical engineering; physics and general engineering; electrical engineering; electronics; information and communication technology; computer software, artificial intelligence and machine learning, automotive; optics, optoelectronics and laser technology; material science; chemistry; pharmaceutics; life sciences including biotech; medical devices and e-health.
UPC-related services: Patent enforcement; defense against infringement claims; proactive revocation claims; defense against revocation claims.
PENTARC has practiced in seven CFI divisions, and before the CoA.
SEP-related services: Advice on FRAND negotiations for SEP holders; advice on FRAND negotiations for implementers; SEP enforcement; defense against SEP infringement claims; bring revocation claims against SEPs (including EPO opposition, PTAB, etc.); bring antitrust-based FRAND claims; defense against antitrust-based FRAND claims; bring contract-based FRAND claims, defense against contract-based FRAND claims; pursuit of antisuit injunctions and interim licenses; defense against antisuit injunction and interim license motions; pursuit of anti-antisuit injunctions; defense against anti-antisuit injunction motions.
UPC achievements
WORK-IN-PROGRESS
Successful infringement defenses (main proceedings)
- Sanofi v. Zentiva (December 12, 2025 – Munich LD):
Double jeopardy takes down Sanofi’s cabazitaxel use patent as UPC’s Munich LD revokes after EPO BoA affirmance – ip fray
Invalidated patents through revocation (counter)claim or EPO opposition
- Sanofi v. Zentiva (December 12, 2025 – Munich LD):
Double jeopardy takes down Sanofi’s cabazitaxel use patent as UPC’s Munich LD revokes after EPO BoA affirmance – ip fray
Settlements
- Adeia v. Disney (December 22, 2025 – The Hague LD):
Disney, Adeia settle global litigation, strike media patent licensing agreement – ip fray
SEP achievements
WORK-IN-PROGRESS